{
  "symbol": "ABBV",
  "name": "AbbVie",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "2012-12-31",
  "headquarters": "North Chicago, Illinois",
  "founded": "2013 (1888)",
  "market_cap": 335209.725952,
  "pe_ratio": 81.44636,
  "forward_pe": 15.644683,
  "eps": 2.33,
  "revenue": 57366.99904,
  "profit_margin": 0.073130004,
  "debt_to_equity": 4789.603,
  "return_on_equity": 0.884,
  "dividend_yield": 3.53,
  "current_price": 189.77000427246094,
  "year_high": 216.65775738076877,
  "year_low": 159.08098459514875,
  "price_change_1d": 0.0,
  "price_change_1w": -0.11579620734893908,
  "price_change_1m": 1.2268645846169723,
  "description": "AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring,",
  "website": "https://www.abbvie.com",
  "employees": 55000,
  "exchange": "NYQ",
  "currency": "USD",
  "analyst_target_price": 209.1237,
  "recommendation": 1.96429,
  "number_of_analysts": 27,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 250.0,
    "target_low": 170.0,
    "target_mean": 209.1237,
    "target_median": 205.0
  },
  "last_updated": "2025-07-09T11:15:59.795017",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}